Biomarker for Infection Risk in CLL and MM

Inclusion Criteria: * Adults ≥18 years of age. * Diagnosis of Rai stage I-IV chronic lymphocytic leukemia or small lymphocytic lymphoma or multiple myeloma. * Subjects must be able to consent to clinical trial, or documented health care proxy agent able to consent on behalf of participant. Exclusion Criteria: * Subjects must not have received IVIG administration within 6 calendar months of registration or have planned immunoglobulin replacement therapy by treating investigator at time of registration. * Subjects with chronic lymphocytic leukemia or small lymphocytic lymphoma must not be Rai stage 0. * Subjects with multiple myeloma must not have smoldering myeloma or solitary plasmacytoma with or without minimal marrow involvement. * Subjects must not have undergone prior autologous, allogeneic stem cell, or solid organ transplant. * Subjects must not have any active systemic infection requiring ongoing antimicrobial treatment (prophylactic antimicrobial allowed) at time of registration. * Subjects must have no known history of HIV, primary immune deficiency disorder, nor be taking a concurrent immune suppressing medication at time of registration. Treatment for CLL/SLL or MM, CLL/SLL related autoimmune phenomenon, or physiologic dosing of corticosteroids (5mg/day prednisone/equivalent or lower) is permitted.